ITCI Intra-Cellular Therapies Inc.

23.24
-0.37  -2%
Previous Close 23.61
Open 22.47
Price To Book 5.68
Market Cap 1,287,936,747
Shares 55,418,965
Volume 1,021,448
Short Ratio
Av. Daily Volume 3,180,135
Stock charts supplied by TradingView

NewsSee all news

  1. Intra-Cellular Therapies Prices Public Offering of Common Stock

    NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 10,000,000

  2. Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

    NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of 10,000,000 shares of its

  3. Intra-Cellular Therapies to Present at the 38th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today

  4. FDA Approves Intra-Cellular Therapies' Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults

    NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today

  5. Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology

    Bipolar depression:  Study 404, A Phase 3 Clinical Trial of lumateperone for the treatment of Bipolar Depression, investigating the potential of lumateperone as a new option for the treatment of depressive episodes in

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial did not meet primary endpoint - July 8, 2019.
ITI-007 - Monotherapy (Study 401)
Bipolar depression
Phase 3 interim analysis December 18, 2018 noted trial to stop due to futility.
ITI-007-201
Agitation in patients with dementia
FDA Approval announced December 23, 2019.
Lumateperone
Schizophrenia
Phase 3 top-line data due mid-2020.
ITI-007-402
Bipolar depression
Phase 3 trial met primary endpoint - July 8, 2019.
ITI-007 - Monotherapy (Study 404)
Bipolar depression
Phase 1/2 top-line presented October 22, 2018.
ITI-214
Parkinson's disease (PD)
Phase 1/2 top-line data due 1H 2020.
ITI-214-105
Heart failure

Latest News

  1. Intra-Cellular Therapies Prices Public Offering of Common Stock

    NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 10,000,000

  2. Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

    NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of 10,000,000 shares of its

  3. Intra-Cellular Therapies to Present at the 38th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today

  4. FDA Approves Intra-Cellular Therapies' Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults

    NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today

  5. Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology

    Bipolar depression:  Study 404, A Phase 3 Clinical Trial of lumateperone for the treatment of Bipolar Depression, investigating the potential of lumateperone as a new option for the treatment of depressive episodes in

  6. Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of Neuropsychopharmacology

    NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today

  7. Intra-Cellular Therapies to Present at the 2019 Cantor Global Healthcare Conference

    NEW YORK, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today

  8. Intra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Translational Medicine Study in Patients with Heart Failure

    Data indicate ITI-214 at a dose of 30 mg is well tolerated with a favorable safety profile Study ‘104 now proceeding to a third cohort at a dose of 90 mg NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular

  9. Intra-Cellular Therapies Provides Lumateperone Regulatory Update

    FDA has informed the Company it has no plans to schedule an Advisory Committee Meeting Company has completed submission of non-clinical information previously agreed with FDA  NEW YORK, Sept. 10, 2019 (GLOBE